EDINA, Minn., Sept. 15, 2026 /PRNewswire/ -- ReEmerge, Inc. (ReEmerge), a private MedTech company innovating a new way to address cognitive impairment, launched from stealth today following the close of an oversubscribed $37M Series A financing. The proceeds will support an upcoming clinical study that will evaluate ReEmerge's proprietary Cognitive Network Restoration Therapy (CNRT) in its first clinical indication, traumatic brain injury (TBI), while advancing technology development, expanding clinical and regulatory operations, and preparing the platform for future indications. U.S. Venture Partners (USVP) and Santé co-led the round, with significant participation from Oxford Science Enterprises, 415 Capital, IAG Capital Partners, The Vertical Group, and Dendrion Ventures.
"ReEmerge's technology represents a fundamentally different approach to cognitive recovery with the potential to transform the recovery pathway," commented Jonathan Root, MD, General Partner at USVP. "The size of the opportunity and the profound unmet need make this an especially compelling market for innovation. We are excited about this technology and the new hope it aims to offer patients and their families."
"TBI does not discriminate. It can happen to anyone at any age, and its consequences can fundamentally alter a person's ability to live, work, and engage with the world around them," said Auriel August, MD, Principal at Santé. "CNRT could offer people living with TBI something they have too often been told not to expect, namely the possibility of meaningful cognitive recovery."
CNRT is a proprietary, first-of-its-kind approach that precisely targets neural networks in the central thalamus, a brain hub involved in attention, arousal, and executive function. Rather than bypassing damaged pathways or asking patients to compensate for lost function, CNRT aims to augment the recovery journey by driving underactive but viable neural circuits. By restoring function across existing but underperforming networks, CNRT aims to reverse cognitive deficits and allow recovery to extend further.
This technology grew out of decades of research by Nicholas Schiff, M.D. Professor of Neuroscience in the Feil Family Brain and Mind Research Institute at Weill Cornell Medicine and colleagues at Stanford University and the University of Utah, which explored the possible restorative effect of brain electrical stimulation after TBI. A pilot study showed promising results, with patients regaining cognitive function. The Center for Technology Licensing at Weill Cornell worked closely with Dr. Schiff's team to protect the intellectual property, provide internal translational gap funding, and license the foundational intellectual property to ReEmerge to advance clinical and commercial development of CNRT.
Building upon this groundbreaking clinical research, including a publication in Nature Medicine, ReEmerge will conduct a prospective, single-arm, multicenter study (NCT07730099) to evaluate this treatment, enrolling up to 40 patients with chronic moderate-to-severe TBI. Additionally, the study will explore potential effects on cognitive and functional outcomes.
"As a physician-scientist and co-founder, it has been very rewarding to see the arc of benchtop science moving forward and being translated into a meaningful clinical development pathway," stated Dr. Schiff. "I am excited for us to advance the testing of treatment for many patients, who have historically had limited therapeutic options, as we look to shift cognitive care from rehabilitation to restoration and ultimately, to redefine recovery."
Each year, an estimated 27 million people worldwide experience a traumatic brain injury, and many are left with persistent cognitive impairment.1 Current recovery pathways focus on rehabilitation, helping patients compensate for cognitive deficits through structured routines, adaptive strategies, and supportive therapies. While these interventions can improve function, the journey can be long, and recovery will often plateau, frequently leaving patients with lasting impairments that limit independence, quality of life, and personhood.
"The strong support of our stellar investor syndicate validates our mission to evolve the recovery trajectory for patients living with impaired cognitive function," said Todd Langevin, Chief Executive Officer of ReEmerge. "We look forward to initiating our clinical study in TBI and building a robust body of evidence to support our differentiated approach to treating cognitive impairment."
About ReEmerge, Inc.
ReEmerge is innovating a new way to approach chronic cognitive impairment. Developed under an exclusive licensing agreement with Cornell University, the company's novel Cognitive Network Restoration Therapy (CNRT) precisely targets neural networks disrupted by brain injury that drive underactive but viable neural circuits. By restoring function across these existing but underperforming networks, CNRT aims to reverse cognitive deficits and restore agency and personhood. To learn more about how the company is developing therapeutic innovations that evolve cognitive care from rehabilitation to restoration, please visit ReEmergeInc.com.
Media Contact
Charlene Herndon
SPRIG Consulting
charlene@sprigconsuting.com
1Guan B, Anderson DB, Chen L, et al. Global, regional and national burden of traumatic brain injury and spinal cord injury, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
BMJ Open 2023;13:e075049. doi: 10.1136/bmjopen-2023-075049
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/reemerge-inc-exits-stealth-with-oversubscribed-37m-series-a-to-challenge-the-limitations-of-chronic-cognitive-impairment-caused-by-brain-injuries-302878979.html
Beim Winterthurer Textilmaschinenhersteller Rieter kommt es zu einem abrupten Führungswechsel. CEO und Verwaltungsratspräsident Thomas Oetterli gibt beide Ämter per Ende Oktober ab. An die Spitze der Geschäftsführung rückt Anfang November der Branchenkenner Daniel Lippuner, während Carl Illi mit sofortiger Wirkung das Präsidium des Verwaltungsrats übernimmt. Rieter begründet den Schritt damit, dass nach der Umsetzung zentraler strategischer Projekte nun der Zeitpunkt gekommen sei, die Verantwortung in neue Hände zu legen.
Lippuner gilt als ausgewiesener Experte für Spinnmaschinen, Garnverarbeitung und Textilkomponenten. Er leitete früher den Textilmaschinenhersteller Saurer und zuvor den Bereich Oerlikon Textile Components. Zudem ist er Verwaltungsratspräsident und Miteigentümer von Heberlein Technology und damit weiterhin eng in der Chemiefaserindustrie verankert. Illi gehört dem Rieter-Verwaltungsrat seit 2017 an und wird vom Unternehmen ebenfalls als Textilexperte charakterisiert. Er soll das Präsidium mindestens bis zur nächsten Generalversammlung führen.
Oetterli, Jahrgang 1969 und früher Chef des Lift- und Rolltreppenherstellers Schindler, war im März 2023 zu Rieter geholt worden, um den bereits damals kriselnden Maschinenbauer zu stabilisieren. Noch im selben Jahr lancierte er das Performance-Programm «Next Level», das ein massives Kostensenkungs- und Restrukturierungspaket umfasst. Der Plan sah unter anderem vor, bis 2025 rund 1400 Vollzeitstellen vorwiegend in Deutschland, der Schweiz und weiteren europäischen Ländern abzubauen und Standorte zu konsolidieren. Parallel dazu übernahm Rieter im Februar die Textilmaschinensparte Barmag von OC Oerlikon, was mit einem deutlichen Anstieg der Verschuldung einherging.
Trotz dieser einschneidenden Massnahmen blieb die erhoffte Trendwende aus. Die Amtszeit Oetterlis war von einem ausserordentlich schwachen Marktumfeld mit anhaltender Nachfrageschwäche geprägt. 2024 hatte er zusätzlich das Präsidium des Verwaltungsrats übernommen – ein Doppelmandat, das den Aktionären ursprünglich als Übergangslösung zur konsequenten Umsetzung von «Next Level» verkauft worden war. Grösster Anteilseigner bei Rieter ist der Schweizer Industrielle Peter Spuhler mit einem Anteil von 33,1 Prozent; er sitzt ebenfalls im Verwaltungsrat. Der Führungswechsel in Winterthur folgt zeitlich auf eine ebenfalls angekündigte Neubesetzung an der Spitze von Stadler Rail, einem weiteren Unternehmen, an dem Spuhler die Kontrolle hält.
